New Two-Drug attack on tough prostate cancer

NCT ID NCT06228053

Summary

This study is testing whether adding an experimental drug called SX-682 to a standard prostate cancer drug (enzalutamide) can help men whose cancer has spread and stopped responding to other hormone therapies. The goal is to see if this combination can control the cancer's growth and extend survival. The trial will enroll about 53 men to measure how well the treatment works and monitor for side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact

    Contact Email: •••••@•••••

  • University of California, Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Email: •••••@•••••

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Email: •••••@•••••

    Contact

  • University of Minnesota

    NOT_YET_RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Email: •••••@•••••

  • University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.